Table 1. NAP1L5 expression with clinicopathological characteristics of patients with HCC.
| Variable | All cases | NAP1L5 density | p-value | |
| Low | High | |||
| n = 45 | n = 44 | |||
| Age (years) | 0.900 | |||
| ≦50 | 19 | 18 | ||
| >50 | 26 | 26 | ||
| Gender | 0.276 | |||
| Female | 3 | 6 | ||
| Male | 42 | 38 | ||
| Vital Status | 0.018 | |||
| Alive | 24 | 34 | ||
| Dead | 21 | 10 | ||
| HbsAg | 0.471 | |||
| Positive | 11 | 8 | ||
| Negative | 34 | 36 | ||
| AFP (ng/mL) | 0.937 | |||
| ≦400 | 28 | 29 | ||
| >400 | 16 | 16 | ||
| ALT level (U/L) | 0.578 | |||
| ≦40 | 25 | 27 | ||
| >40 | 20 | 17 | ||
| Cirrhosis | 0.699 | |||
| Yes | 4 | 5 | ||
| No | 41 | 39 | ||
| Tumor size (cm) | 0.667 | |||
| ≤6 | 33 | 34 | ||
| >6 | 12 | 10 | ||
| AJCC Stage | 0.691 | |||
| I | 31 | 32 | ||
| II–III | 14 | 12 | ||
| Histological Grade | 0.169 | |||
| I–II | 18 | 24 | ||
| III | 27 | 20 | ||
| Involucrum | 0.169 | |||
| Complete | 27 | 20 | ||
| Incomplete or absent | 18 | 24 | ||
| Recurrence | 0.015 | |||
| Yes | 15 | 26 | ||
| No | 30 | 18 | ||
We divided the patients into high expression group and low expression group according to the expression of NAP1L5. Patients and disease were compared in each group.